These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30420296)

  • 1. Treatment of heritable diseases using CRISPR: Hopes, fears, and reality.
    Kofler N; Kraschel KL
    Semin Perinatol; 2018 Dec; 42(8):515-521. PubMed ID: 30420296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR in personalized medicine: Industry perspectives in gene editing.
    Hong A
    Semin Perinatol; 2018 Dec; 42(8):501-507. PubMed ID: 30376985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In search of: Suggesting a course of action for the scientific community to research potential impacts of heritable gene editing on the maternal carrier.
    Gravelle R
    Semin Perinatol; 2018 Dec; 42(8):522-524. PubMed ID: 30482592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR: express delivery to any DNA address.
    Peterson A
    Oral Dis; 2017 Jan; 23(1):5-11. PubMed ID: 27040868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
    Salsman J; Masson JY; Orthwein A; Dellaire G
    Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations.
    Memi F; Ntokou A; Papangeli I
    Semin Perinatol; 2018 Dec; 42(8):487-500. PubMed ID: 30482590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The CRISPR-Cas system: beyond genome editing].
    Croteau FR; Rousseau GM; Moineau S
    Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Progress in Genome Editing Approaches for Inherited Cardiovascular Diseases.
    Kaur B; Perea-Gil I; Karakikes I
    Curr Cardiol Rep; 2018 Jun; 20(7):58. PubMed ID: 29860642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hope and Hype of CRISPR-Cas9 Genome Editing: A Review.
    Musunuru K
    JAMA Cardiol; 2017 Aug; 2(8):914-919. PubMed ID: 28614576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
    Zhang X; Wang L; Liu M; Li D
    Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Editing and Genetic Lung Disease. Basic Research Meets Therapeutic Application.
    Alapati D; Morrisey EE
    Am J Respir Cell Mol Biol; 2017 Mar; 56(3):283-290. PubMed ID: 27780343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Therapeutic Genome Editing in China.
    Yang Y; Wang Q; Li Q; Men K; He Z; Deng H; Ji W; Wei Y
    Hum Gene Ther; 2018 Feb; 29(2):136-145. PubMed ID: 29446996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR editing in biological and biomedical investigation.
    Huang J; Wang Y; Zhao J
    J Cell Physiol; 2018 May; 233(5):3875-3891. PubMed ID: 28786481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 therapeutics for liver diseases.
    Aravalli RN; Steer CJ
    J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. User-Friendly Technology the Key to Gene-Editing's Bloom: Market for Gene-Editing Tools Estimated at $608m and Growing as New Applications Are Found.
    Carlson B
    Hum Gene Ther Clin Dev; 2016 Dec; 27(4):137-139. PubMed ID: 27983891
    [No Abstract]   [Full Text] [Related]  

  • 20. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
    Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.